The content on this site is intended for healthcare professionals only
At SIOG 2014, Prof Kataja speaks to ecancertv about the challenges of using new cancer therapeutics on the elderly population.
The latest therapeutics, such as targeted therapies, are rarely trialled on the elderly - what implications does this have for treatment?
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC
Immunotherapy resistance pathways investigated to tailor combination NSCLC therapy
ESMO 2024: Latest in EGFR mutated NSCLC
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
ASCO 2024: Lung cancer highlights
More effective treatment options required for patients with MM post lenalidomide exposure
